Janssen Pharmaceutica Nv

Araxes Pharma LLC

Jimmy T Liang

Neelakandha S Mani

Xiaohu Deng

Curt A Dvorak

Gang Chen

Nicholas I Carruthers

Wenying Chai

Dale A Rudolph

Christa C Chrovian

Brett D Allison

Chennagiri R Pandit

Annette K Kwok

Victoria Wong

Chaofeng Huang

Pingda Ren

Liansheng Li

Cheryl A Grice

Michael Anthony Letavic

Yun Long

Heather Renee Coate

Brad M Savall

Devin M Swanson

Laurent Gomez

Yuan Liu

John J M Wiener

Michael K Ameriks

Christine Fang Gelin

Brice M Stenne

Akinola Soyode-Johnson

Jason Christopher Rech

Genesis M Bacani

Virginia M Tanis

Jessica L Wall

Jose Ignacio Andres Gil

Susanne Lochner

Manuel Jesus Alcazar Vaca

Alejandro Santillán, Jr

Alice Lee-Dutra

Brian Ngo Laforteza

Pablo Garcia-Reynaga

Meri De Angelis

Kathleen C Sappey

Diego Broggini

Aaron M Kearney

Zachary S Sales

Adrienne M Landry-Bayle

Hartmut B Zinser

Cynthia B Berry

Kia Sepassi

Eugene Y Cheung

Alvah T Wickboldt

Kathleen C Sappy

Alejandro Santillan

Anne M Fourine

John JM Wiener

Victoria D Wong

John J Wiener

Anne M Fourie

The present invention relates to novel, selective, radiolabelled compound having monoacylglycerol lipase (MGL) affinity which are useful for imaging and quantifying MGL receptor expression, distribution and enzyme occupancy in tissues, using positron-emission tomography (PET). The invention is also directed to compositions comprising such compounds, the use of such compounds and compositions for imaging a tissue, cells or a host, in vitro or in vivo and to precursors of said compounds.

Radiolabelled MGL PET ligands

Radiolabelled MGL pet ligands

3.1.0 and 4.1.0 Azabicycle compounds of Formula (I), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions. wherein X, Y, R, R, and Rare defined herein.

Monoacylglycerol lipase modulators

The present invention is directed to compounds of Formulas (I, Ia, IIa and IIb). The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, Ia, IIa and IIb). Methods of making and using the compounds of Formulas (I, Ia, IIa and IIb) are also within the scope of the invention. 

P2X7 modulators and methods of use

Methods for preparing compounds having the following structure (I): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein R, R, R, R, R, R, Rand R, are as defined herein are provided. Related compounds and methods for making the same are also provided.

Methods for preparation of quinazoline derivatives

Certain methods that are useful in the preparation of amidophenyl-sulfonylamino-quinoxaline compounds are disclosed. The compounds are of the class of quinoxaline sulfonamides and constitute CCK2 receptor modulators, useful in the treatment of gastrointestinal diseases.

Preparation of quinoxaline compounds

Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amine compounds are described, which are useful as LTA4 hydrolase (LTA4H) modulators. Such compounds may be used in pharmaceutical compositions and methods for modulation of LTA4H and for the treatment of disease states, disorders, and conditions mediated by LTA4 hydrolase activity.

Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase

The present invention is directed to novel processes for the preparation of fused pyrazole compounds, useful for the treatment of disorders and conditions mediated by serotonin receptor activity.

Methods for the preparation of pyrazole-containing compounds

Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.

Fused heterocyclic compounds

Certain methods are disclosed that are useful in the preparation of CCK2 active amidophenyl-sulfonylamino-quinoxaline compounds of the formula: wherein R, R, Rand Rare defined.

Growing community of inventors

San Diego, CA, United States of America

Jimmy T Liang